Furthermore, the combination therapy exhibited a synergistic effect with a CI < 1; registering at 0.8 for DHT levels, 0.87 for PSA levels and 0.88 for AR mRNA expression, indicating that the FIN/HCQ combination offers a more effective treatment regimen than individual therapies in impeding BPH progression. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.